- Home
- LRE vs IGC Comparison
LRE vs IGC Comparison
Compare LRE & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- IGC
- Stock Information
- Founded
- LRE 2001
- IGC 2005
- Country
- LRE Japan
- IGC United States
- Employees
- LRE N/A
- IGC N/A
- Industry
- LRE
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- IGC Health Care
- Exchange
- LRE Nasdaq
- IGC Nasdaq
- Market Cap
- LRE 17.6M
- IGC 20.2M
- IPO Year
- LRE 2023
- IGC N/A
- Fundamental
- Price
- LRE $1.20
- IGC $0.29
- Analyst Decision
- LRE
- IGC Strong Buy
- Analyst Count
- LRE 0
- IGC 2
- Target Price
- LRE N/A
- IGC $3.88
- AVG Volume (30 Days)
- LRE 10.4K
- IGC 196.9K
- Earning Date
- LRE 01-01-0001
- IGC 06-23-2025
- Dividend Yield
- LRE N/A
- IGC N/A
- EPS Growth
- LRE N/A
- IGC N/A
- EPS
- LRE 0.29
- IGC N/A
- Revenue
- LRE $117,804,154.00
- IGC $1,236,000.00
- Revenue This Year
- LRE N/A
- IGC N/A
- Revenue Next Year
- LRE N/A
- IGC $16.45
- P/E Ratio
- LRE $4.10
- IGC N/A
- Revenue Growth
- LRE 8.82
- IGC 1.65
- 52 Week Low
- LRE $1.10
- IGC $0.25
- 52 Week High
- LRE $13.76
- IGC $0.62
- Technical
- Relative Strength Index (RSI)
- LRE 46.94
- IGC 46.51
- Support Level
- LRE $1.22
- IGC $0.28
- Resistance Level
- LRE $1.29
- IGC $0.32
- Average True Range (ATR)
- LRE 0.12
- IGC 0.01
- MACD
- LRE -0.01
- IGC -0.00
- Stochastic Oscillator
- LRE 12.20
- IGC 26.50
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.